Last updated: February 6, 2024
Sponsor: Duke University
Overall Status: Completed
Phase
4
Condition
Pressure Ulcer
Treatment
QL Block
Liposomal Bupivicaine
Clinical Study ID
NCT03496610
Pro00087144
Ages 18-75 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- English speaking
- ASA 1-2 patients undergoing living donor nephrectomy
Exclusion
Exclusion Criteria:
- ASA 3 or 5
- Diagnosis of chronic pain
- Daily chronic opioid use (over 3 months of continuous opioid use)
- Inability to communicate pain scores or need for analgesia
- Infection at the site of block placement
- Pregnant women (as determined by standard of care day-of surgery urine bHCG)
- Intolerance/allergy to local anesthetics
- Weight <50 kg
- Suspected or known addiction to or abuse of illicit drug(s), prescription medicine(s),or alcohol within the past 2 years
- Uncontrolled anxiety, schizophrenia, or other psychiatric disorder that, in theopinion of the investigator, may interfere with study assessments or compliance
- Current or historical evidence of any clinically significant disease or conditionthat, in the opinion of the investigator, may increase the risk of surgery orcomplicate the subject's postoperative course
Study Design
Total Participants: 44
Treatment Group(s): 2
Primary Treatment: QL Block
Phase: 4
Study Start date:
January 25, 2021
Estimated Completion Date:
February 23, 2023
Connect with a study center
Duke University
Durham, North Carolina 27705
United StatesSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.